Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Public ClinicalTrials.gov record NCT03070093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to provide expanded access to ASP2215 for subjects with FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission (CRc) (complete remission \[CR\], complete remission with incomplete hematologic recovery \[CRi\], complete remission with incomplete platelet recovery \[CRp\]) with MRD without access to comparable or alternative therapy.
Study identification
- NCT ID
- NCT03070093
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Apr 19, 2021
United States locations
- U.S. sites
- 32
- U.S. states
- 21
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA | Los Angeles | California | 90095 | — |
| Rocky Mountain Cancer Center-M | Aurora | Colorado | 80012 | — |
| Memorial Healthcare System | Pembroke Pines | Florida | 33028 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | — |
| Northwestern University Medical Center | Chicago | Illinois | 60611 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Indiana Blood and Marrow Transplantation at Franciscan Health Indianapolis | Indianapolis | Indiana | 45237 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Tulane University | New Orleans | Louisiana | 70112 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| The Sidney Kimmel Comprehensive Cancer Center -Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| West Michigan Regional Cancer Center | Kalamazoo | Michigan | 49007 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| New Mexico Cancer Care Alliance | Albuquerque | New Mexico | 87106 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Memorial Sloan Kettering | New York | New York | 10021 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Wake Forest Baptist Hospital | Winston-Salem | North Carolina | 27157 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Penn State Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19066 | — |
| UPCI | Pittsburgh | Pennsylvania | 15232 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| Huntsman Cancer Institute University of Utah | Salt Lake City | Utah | 84112 | — |
| WVU Medicine Cancer | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03070093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2021 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03070093 live on ClinicalTrials.gov.